Immunic Inc. (IMUX)
| Bid | 1.02 |
| Market Cap | 99.99M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -100.51M |
| EPS (ttm) | -1 |
| PE Ratio (ttm) | -1.11 |
| Forward PE | -1.56 |
| Analyst | Buy |
| Ask | 1.19 |
| Volume | 382,586 |
| Avg. Volume (20D) | 712,761 |
| Open | 1.17 |
| Previous Close | 1.14 |
| Day's Range | 1.09 - 1.17 |
| 52-Week Range | 0.83 - 2.11 |
| Beta | 1.92 |
About IMUX
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company i...
Analyst Forecast
According to 7 analyst ratings, the average rating for IMUX stock is "Buy." The 12-month stock price forecast is $13.5, which is an increase of 1116.22% from the latest price.
Stock Forecasts
2 weeks ago · proactiveinvestors.com
Immunic announces pricing of $5.1M direct offering to support clinical pipelineImmunic Inc (NASDAQ:IMUX) has priced its $5.1 million registered direct offering led by Aberdeen Investments, selling 5.67 million shares at $0.90 each. The biotechnology company, which is advancing o...
1 month ago · proactiveinvestors.com
Biotechs challenge big pharma with new oral weight loss therapiesWith the smash success of glucagon-like peptide-1 (GLP-1) agonists as a treatment for obesity, pharmaceutical giants and emerging biotechnology firms alike are working to develop an equally effective ...
1 month ago · proactiveinvestors.com
Immunic to highlight vidofludimus calcium's potential as MS therapy at upcoming forumImmunic Inc (NASDAQ:IMUX) announced that it will present key data for its investigational drug vidofludimus calcium in two poster presentations at the Americas Committee for Treatment and Research in ...
2 months ago · proactiveinvestors.com
Immunic drug candidate may offer new obesity treatment - ICYMIImmunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt joined Proactive to discuss the company's latest findings on IMU-856, a drug candidate initially studied for celiac disease. New data suggests that IMU-856...
2 months ago · proactiveinvestors.com
Immunic highlights IMU-856's potential as weight management therapyImmunic Inc (NASDAQ:IMUX) has released new data that supports the potential of its investigational therapeutic IMU-856 as an oral treatment for weight management. IMU-856, a small molecule that target...